| Literature DB >> 30861998 |
Jarosław Marusiak1, Beth E Fisher2, Anna Jaskólska3, Krzysztof Słotwiński4, Sławomir Budrewicz5, Magdalena Koszewicz6, Katarzyna Kisiel-Sajewicz7, Bartosz Kamiński8, Artur Jaskólski9.
Abstract
BACKGROUND: This study examined the generalized effects of cycle ergometer aerobic interval training (AIT) on psychomotor behaviors in individuals with Parkinson's disease (PD), including bimanual motor control, cognitive function, and neurological motor and non-motor parkinsonian signs.Entities:
Keywords: Parkinson’s disease; aerobic interval training; bimanual motor control; executive function; neuroplasticity
Mesh:
Year: 2019 PMID: 30861998 PMCID: PMC6427316 DOI: 10.3390/ijerph16050880
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow diagram.
Clinical and anthropometric characteristics of the Parkinson’s disease (PD) patients in the training (PD-TR, n = 10) and control (PD-CO, n = 10) groups.
| PD Patient No. | Age (Years) | Sex (F/M) | Body Mass (kg) | Height (cm) | Disease Onset/Duration (Years) | Affected Upper Limb (R/L) | Dominant Upper Limb (R/L) | Hoehn and Yahr (Points) |
|---|---|---|---|---|---|---|---|---|
| PD-TR#01 | 79 | M | 71 | 157 | 69/10 | R | R | 2.5 |
| PD-TR#02 | 65 | F | 64 | 162 | 58/7 | L | R | 2.5 |
| PD-TR#03 | 68 | M | 78 | 167 | 55/13 | R | R | 2.5 |
| PD-TR#04 | 65 | F | 61 | 155 | 63/2 | R | R | 1.5 |
| PD-TR#05 | 60 | M | 79 | 169 | 46/14 | R | R | 3.0 |
| PD-TR#06 | 84 | M | 73 | 165 | 80/4 | L | R | 1.5 |
| PD-TR#07 | 68 | M | 67 | 177 | 56/12 | L | R | 2.5 |
| PD-TR#08 | 78 | F | 67 | 159 | 70/8 | L | R | 3.0 |
| PD-TR#09 | 62 | M | 63 | 161 | 46/16 | R | R | 3.0 |
| PD-TR#10 | 88 | F | 67 | 149 | 84/4 | L | R | 2.0 |
| Mean ± SD | 72 ± 10 | - | 69 ± 9 | 162 ± 8 | 63 ± 13/9 ± 5 | - | - | 2.35 ± 0.57 |
| PD-CO#01 | 81 | F | 63 | 159 | 71/10 | L | R | 3.0 |
| PD-CO#02 | 67 | F | 64 | 156 | 63/4 | R | R | 2.0 |
| PD-CO#03 | 81 | M | 67 | 157 | 59/12 | R | R | 2.0 |
| PD-CO#04 | 90 | F | 60 | 148 | 84/6 | L | R | 2.0 |
| PD-CO#05 | 79 | F | 60 | 156 | 69/8 | L | R | 2.5 |
| PD-CO#06 | 72 | M | 78 | 182 | 61/11 | R | R | 2.0 |
| PD-CO#07 | 60 | F | 67 | 153 | 52/8 | R | R | 2.0 |
| PD-CO#08 | 74 | F | 59 | 164 | 69/5 | R | R | 1.5 |
| PD-CO#09 | 66 | F | 70 | 160 | 64/2 | L | R | 1.5 |
| PD-CO#10 | 70 | M | 76 | 166 | 55/15 | R | R | 3.0 |
| Mean ± SD | 74 ± 9 | - | 66 ± 7 | 160 ± 9 | 66 ± 9/8 ± 4 | - | - | 2.25 ± 0.53 |
Abbreviations: No.—number; F—female; M—male; R—right side; L—left side; ±SD—standard deviation.
Figure 2Images describing the set-up (panel A) and our custom-made device (panel B) used for the anti-phase bimanual motor control measurements.
Figure 3Comparison of the bimanual motor control outcomes between the two testing sessions and the two tested groups. (A) panel A presenting the values of time GFman dev; (B) panel B presenting the values of rate GFman dev; (C) panel C presenting the values of time GFs del man-stab; (D) panel D presenting the values of GFman; (E) panel E presenting the values of 100% LF; (F) panel F presenting the values of 20% LF; (G) panel G presenting the values of time 20% LF dev; (H) panel H presenting the values of rate 20% LF dev. Abbreviations: PRE—testing session before the eight weeks of training; POST—testing session after the eight weeks of training; PD-TR—Parkinson’s disease patients from the training group; PD-CO—Parkinson’s disease patients from the control group; GFman—peak value of grip force in the manipulating hand during the 20% load force trial; time GFman dev—time taken for GFman development; rate GFman dev—rate of GFman development; time GFs del man-stab—time delay between the onset of grip force development in the manipulating hand and that in the stabilizing hand; 100% LF—the value of achieved maximal load force; 20% LF—the peak value of developed LF during the trial of 20% LF; time 20% LF dev—the time taken for 20% LF development; rate 20% LF dev—the rate of 20% LF development; the % value inserted into the bar of the POST session indicates the percentage value of the change between the POST and PRE testing sessions; *—statistically significant inter-testing session or inter-group difference at the p ≤ 0.05 level.
Significance (p) and effect size (d) values for the parameter comparisons between the testing sessions (POST vs. PRE) and the tested groups (PD-TR, n = 10 vs. PD-CO, n = 10).
| Parameters | POST vs. PRE Comparison | PD-TR vs. PD-CO Comparison | |||
|---|---|---|---|---|---|
| PD-TR | PD-CO | PRE | POST | ||
| Bimanual Motor Control Outcomes | time GFman dev | ||||
| rate GFman dev | |||||
| time GFs del man-stab | |||||
| GFman | |||||
| 100% LF | |||||
| 20% LF | |||||
| time 20% LF dev | |||||
| rate 20% LF dev | |||||
| Psychological Outcomes | TMT-A | ||||
| TMT-B | |||||
| ST-I | |||||
| ST-II | |||||
| Neurological Outcomes | Brad.-UEUPDRS 23 | ||||
| DLMFUPDRS 8–11 | |||||
| Int.Beh. UPDRS 1–4 | |||||
| S&E DLA | |||||
Abbreviations: PRE—testing session before the eight weeks of training; POST—testing session after the eight weeks of training; PD-TR—Parkinson’s disease patients from the training group; PD-CO—Parkinson’s disease patients from the control group; GFman—peak value of grip force in the manipulating hand during the 20% load force trial; time GFman dev—time taken for GFman development; rate GFman dev—rate of GFman development; time GFs del man-stab—time delay between the onset of GF development in the manipulating hand and that in the stabilizing hand; 100% LF—the achieved maximal value of load force; 20% LF—the peak value of developed LF during the 20% LF trial; time 20% LF dev—the time taken for 20% LF development; rate 20% LF dev—the rate of 20% LF development; TMT-A—part A of the Trail Making Test; TMT-B—part B of the Trail Making Test; ST-I—part I of the Stroop Test; ST-II—part II of the Stroop Test; UPDRS—Unified Parkinson’s Disease Rating Scale; Brad.-UEUPDRS 23—bradykinesia of the upper extremity based on point 23 from the UPDRS; DLMFUPDRS 8–11—daily life manual functions based on the sum of points 8–11 from the UPDRS; Int.Beh. UPDRS 1–4—intellectual and emotional state based on the sum of points 1–4 from the UPDRS. S&E DLA scale—Schwab and England Daily Living Activity Scale; p—significance value of the inter-testing session or inter-group comparison; d—the Cohen effect size value for the both factors (testing session and tested group); a value of 0 indicated no effect, whereas values >0.2, ~0.6, and >0.8 indicated small, moderate, and large effects, respectively; * statistically significant inter-testing session or inter-group difference at the p ≤ 0.05 level.
Figure 4Comparison of psychological cognitive outcomes between the two testing sessions and the two tested groups. (A) panel A presenting the values of TMT-A; (B) panel B presenting the values of TMT-B; (C) panel C presenting the values of ST-I; (D) panel D presenting the values of ST-II. Abbreviations: PRE—testing session before the eight weeks of training; POST—testing session after the eight weeks of training; PD-TR—Parkinson’s disease patients from the training group; PD-CO—Parkinson’s disease patients from the control group; TMT-A—part A of the Trail Making Test; TMT-B—part B of the Trail Making Test; ST-I—part I of the Stroop Test; ST-II—part II of the Stroop Test; *—statistically significant inter-testing session or inter-group difference at the p ≤ 0.05 level; the % value inserted into the bar of the POST session indicates the percentage value of the change between the POST and PRE testing sessions.
Figure 5Comparison of neurological outcomes between the two testing sessions and two tested groups. (A) panel A presenting the values of Brad.-UEUPDRS 23; (B) panel B presenting the values of DLMFUPDRS 8–11; (C) panel C presenting the values of Int.Beh. UPDRS 1–4; (D) panel D presenting the values of S&E DLA scale. Abbreviations: PRE—testing session before the eight weeks of training; POST—testing session after the eight weeks of training; PD-TR—Parkinson’s disease patients from the training group; PD-CO—Parkinson’s disease patients from the control group; UPDRS—Unified Parkinson’s Disease Rating Scale; Brad.-UEUPDRS 23—bradykinesia of the upper extremity based on point 23 from the UPDRS; DLMFUPDRS 8–11—daily life manual functions based on the sum of points 8–11 from the UPDRS; Int.Beh. UPDRS 1–4—intellectual and emotional state based on the sum of points 1–4 from the UPDRS; S&E DLA scale—Schwab and England Daily Living Activity Scale; *—statistically significant inter-testing session or inter-group difference at the p ≤ 0.05 level; the % value inserted into the bar of the POST session indicates the percentage value of the change between the POST and PRE testing sessions.